231 related articles for article (PubMed ID: 32148495)
1. AXL as a Target in Breast Cancer Therapy.
Colavito SA
J Oncol; 2020; 2020():5291952. PubMed ID: 32148495
[TBL] [Abstract][Full Text] [Related]
2. AXL Receptor Tyrosine Kinase as a Promising Therapeutic Target Directing Multiple Aspects of Cancer Progression and Metastasis.
Goyette MA; Côté JF
Cancers (Basel); 2022 Jan; 14(3):. PubMed ID: 35158733
[TBL] [Abstract][Full Text] [Related]
3. The Role of the Receptor Tyrosine Kinase Axl in Carcinogenesis and Development of Therapeutic Resistance: An Overview of Molecular Mechanisms and Future Applications.
Wium M; Ajayi-Smith AF; Paccez JD; Zerbini LF
Cancers (Basel); 2021 Mar; 13(7):. PubMed ID: 33806258
[TBL] [Abstract][Full Text] [Related]
4. AXL Receptor Tyrosine Kinase as a Therapeutic Target in Hematological Malignancies: Focus on Multiple Myeloma.
Yan S; Vandewalle N; De Beule N; Faict S; Maes K; De Bruyne E; Menu E; Vanderkerken K; De Veirman K
Cancers (Basel); 2019 Nov; 11(11):. PubMed ID: 31694201
[TBL] [Abstract][Full Text] [Related]
5. AXL receptor tyrosine kinase as a therapeutic target in NSCLC.
Okimoto RA; Bivona TG
Lung Cancer (Auckl); 2015; 6():27-34. PubMed ID: 28210148
[TBL] [Abstract][Full Text] [Related]
6. The Receptor Tyrosine Kinase AXL in Cancer Progression.
Rankin EB; Giaccia AJ
Cancers (Basel); 2016 Nov; 8(11):. PubMed ID: 27834845
[TBL] [Abstract][Full Text] [Related]
7. Quantitative Tyrosine Phosphoproteome Profiling of AXL Receptor Tyrosine Kinase Signaling Network.
Wu X; Wang L; Pearson NA; Renuse S; Cheng R; Liang Y; Mun DG; Madugundu AK; Xu Y; Gill PS; Pandey A
Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439388
[TBL] [Abstract][Full Text] [Related]
8. Function of Axl receptor tyrosine kinase in non-small cell lung cancer.
Zhang G; Wang M; Zhao H; Cui W
Oncol Lett; 2018 Mar; 15(3):2726-2734. PubMed ID: 29434997
[TBL] [Abstract][Full Text] [Related]
9. The Development of AXL Inhibitors in Lung Cancer: Recent Progress and Challenges.
Sang YB; Kim JH; Kim CG; Hong MH; Kim HR; Cho BC; Lim SM
Front Oncol; 2022; 12():811247. PubMed ID: 35311091
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic Targeting of AXL Receptor Tyrosine Kinase Inhibits Tumor Growth and Intraperitoneal Metastasis in Ovarian Cancer Models.
Kanlikilicer P; Ozpolat B; Aslan B; Bayraktar R; Gurbuz N; Rodriguez-Aguayo C; Bayraktar E; Denizli M; Gonzalez-Villasana V; Ivan C; Lokesh GLR; Amero P; Catuogno S; Haemmerle M; Wu SY; Mitra R; Gorenstein DG; Volk DE; de Franciscis V; Sood AK; Lopez-Berestein G
Mol Ther Nucleic Acids; 2017 Dec; 9():251-262. PubMed ID: 29246304
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic activity of DCC-2036, a novel tyrosine kinase inhibitor, against triple-negative breast cancer patient-derived xenografts by targeting AXL/MET.
Shen Y; Zhang W; Liu J; He J; Cao R; Chen X; Peng X; Xu H; Zhao Q; Zhong J; Ding W; Lei X; Jiang Y; Zu X
Int J Cancer; 2019 Feb; 144(3):651-664. PubMed ID: 30289981
[TBL] [Abstract][Full Text] [Related]
12. The Significance of Tumor Budding and Immunohistochemical Axl Expression in Gallbladder Adenocarcinomas.
Öz Ö; Argon A; Kebat T; Namlı Akıncı Ç; Özdemir Ö
Balkan Med J; 2022 May; 39(3):199-208. PubMed ID: 35430785
[TBL] [Abstract][Full Text] [Related]
13. Incorporation of SKI-G-801, a Novel AXL Inhibitor, With Anti-PD-1 Plus Chemotherapy Improves Anti-Tumor Activity and Survival by Enhancing T Cell Immunity.
Lee W; Kim DK; Synn CB; Lee HK; Park S; Jung DS; Choi Y; Kim JH; Byeon Y; Kim YS; Lee S; Lee S; Joo Y; Lee EJ; Yun MR; Heo SG; Yang W; Jung JE; Kim EK; Park J; Park JD; Lee DJ; Kim HW; Lim SM; Hong MH; Ahn BC; Lee JB; Pyo KH
Front Oncol; 2022; 12():821391. PubMed ID: 35356198
[TBL] [Abstract][Full Text] [Related]
14. AXL knockdown gene signature reveals a drug repurposing opportunity for a class of antipsychotics to reduce growth and metastasis of triple-negative breast cancer.
Goyette MA; Cusseddu R; Elkholi I; Abu-Thuraia A; El-Hachem N; Haibe-Kains B; Gratton JP; Côté JF
Oncotarget; 2019 Mar; 10(21):2055-2067. PubMed ID: 31007848
[TBL] [Abstract][Full Text] [Related]
15. Synergistic Induction of Apoptosis by the Combination of an Axl Inhibitor and Auranofin in Human Breast Cancer Cells.
Ryu YS; Shin S; An HG; Kwon TU; Baek HS; Kwon YJ; Chun YJ
Biomol Ther (Seoul); 2020 Sep; 28(5):473-481. PubMed ID: 32536618
[TBL] [Abstract][Full Text] [Related]
16. A dual MET/AXL small-molecule inhibitor exerts efficacy against gastric carcinoma through killing cancer cells as well as modulating tumor microenvironment.
Zhu C; Shi H; Wu M; Wei X
MedComm (2020); 2020 Jun; 1(1):103-118. PubMed ID: 34766112
[TBL] [Abstract][Full Text] [Related]
17. The Emerging Role of TYRO3 as a Therapeutic Target in Cancer.
Smart SK; Vasileiadi E; Wang X; DeRyckere D; Graham DK
Cancers (Basel); 2018 Nov; 10(12):. PubMed ID: 30501104
[TBL] [Abstract][Full Text] [Related]
18. Axl signaling is an important mediator of tumor angiogenesis.
Tanaka M; Siemann DW
Oncotarget; 2019 Apr; 10(30):2887-2898. PubMed ID: 31080559
[TBL] [Abstract][Full Text] [Related]
19. Axl inhibition induces the antitumor immune response which can be further potentiated by PD-1 blockade in the mouse cancer models.
Guo Z; Li Y; Zhang D; Ma J
Oncotarget; 2017 Oct; 8(52):89761-89774. PubMed ID: 29163786
[TBL] [Abstract][Full Text] [Related]
20. Axl-EGFR receptor tyrosine kinase hetero-interaction provides EGFR with access to pro-invasive signalling in cancer cells.
Vouri M; Croucher DR; Kennedy SP; An Q; Pilkington GJ; Hafizi S
Oncogenesis; 2016 Oct; 5(10):e266. PubMed ID: 27775700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
